Intravenous immunoglobulins for multiple sclerosis

Cochrane Database of Systematic Reviews

Volumn 2010, Issue 2, 2003, Pages

  Gray, Orla ^a   McDonnell, Gavin V ^a   Forbes, Raeburn B ^b  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b CRAIGAVON AREA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 24944504173     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002936     Document Type: Review

References (26)

1. Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y, Gornish M, et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998;50(2):398-402.
2. Fazekas F, Strasser-Fuchs S, Nahler G, Mamoli B for The Austrian Immunoglobulin in Multiple Sclerosis Study Group. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997;349(9052):589-93.
3. Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, et al. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis. Neurology 2008;71:265-71.
4. Hommes OR, Sorensen PS, Fazekas F, Maas-Enriquez M, Koelmel HW, Fernandez O, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 2004;364:1149-56.
5. Lewanska M, Siger-Zajdel M, Selmaj K. No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. European Journal of Neurology 2002;9:565-72.
6. Poehlau D, Przuntek H, Sailer M, Bethke F, Koehler J, Koenig N, et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Multiple Sclerosis 2007;13:1107-17.
7. Noseworthy JH, O'Brien PC, Weinshenker BG, Weis JA, Petterson TM, Erickson BJ, et al. IV immunoglobulin does not reverse established weakness in MS. Neurology 2000;55(8):1135-43.
8. Noseworthy JH, O'Brien PC, Petterson TM, Weis T, Stevens L, Peterson WK, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001;56(11):1514-22.
9. Sorenson PS, Wanscher B, Jensen CV, Schreiber K, Blinkenberg M, Ravnborg M, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998;50(5):1273-81.
10. Teksam T, Tali T, Kocer B, Isik S. Qualititative and quantitative volumetric evaluation of the efficacy of intravenous immunoglobulin in multiple sclerosis: preliminary report. Neuroradiology 2000;42(12):885-9.
11. Association of British Neurologists. Guidelines for the use of intravenous immunoglobulin in neurological disease. Guidelines for the use of intravenous immunoglobulin in neurological disease. London, UK, July 2005.
12. Branagan TH, Nagle KJ, Lange DJ, Rowland LP. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996;47(3):674-7.
13. D'Amico R, Ebers G, Filippini G, Fredrikson S, Di Pietrantonj C, Rice GPA, et al. Cochrane Multiple Sclerosis Group. In: The Cochrane Library. 2008, Issue 2. Chichester: Wiley-Blackwell. Updated quarterly.
14. Hawkins SA, McDonnell GV. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. Journal of Neurology Neurosurgery and Psychiatry 1999;67(2):148-52.
15. Hughes RA, Sharrack B. More immunotherapy for multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 1996;61(3):239-41.
16. The IFNB Multiple Sclerosis Study Group. Interferon beta1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double blind, placebo controlled trial. Neurology 1993;43(4):655-61.
17. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33(11):1444-52.
18. Lefebvre C, Manheimer E, Glanville J. Chapter 6: searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
19. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46(4):907-11.
20. Martinelli Boneschi F, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD002127]
21. Noseworthy JH, O'Brien PC, van Engelen BGM, Rodriguez M. Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theilers virus model to a randomised, double blind, placebo controlled clinical trial. Neurology 1994;57(suppl):11-4.
22. Poleman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomised, placebo-controlled trial of natalizumab for relapsing remitting multiple sclerosis. New England Journal of Medicine 2006;354(9):899-910.
23. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for clinical protocol research. Annals of Neurology 1983;13(3):227-31.
24. Rodriguez M, Lennon VA, Benveniste EN, Merrill JE. Remyelination by oligodendrocytes stimulated by antiserum to spinal cord. Journal of Neuropathology and Experimental Neurology 1987;46(1):84-95.
25. Rodriguez M, Lennon VA. Immunoglobulin promotes remyelination in the central nervous system. Annals of Neurology 1990;27(1):12-7.
26. Thornton CA, Ballow M. Safety of intravenous immunoglobulin. Archives of Neurology 1993;50(2):135-6.